Amondys 45 Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited dmd treatment options, orphan drug incentives, genetic testing expansion, early antisense research, patient advocacy efforts.

The growth in the forecast period can be attributed to advancements in gene-based therapies, broader newborn screening, expansion of exon-specific drugs, sustained regulatory fast tracking, increasing clinical trial investments. Major trends in the forecast period include growth of exon skipping therapies, expansion of precision genetic medicine, increased focus on rare neuromuscular disorders, early diagnosis driven targeted treatments, rising regulatory support for orphan drugs.

The increasing prevalence of genetic disorders is expected to drive the growth of the amondys 45 market in the coming years. A genetic disorder is a medical condition caused by abnormalities in an individual’s DNA, which may arise from mutations in one or more genes, chromosomal alterations, or a combination of genetic and environmental factors. The rising incidence of genetic diseases is largely attributed to greater awareness and advancements in diagnostic technologies, which allow earlier and more accurate identification of conditions that were previously undiagnosed. Amondys 45 supports the management of genetic disorders by targeting specific dystrophin gene mutations, making it suitable for patients with Duchenne muscular dystrophy who require exon 45 skipping. It helps improve muscle function by enabling the production of a functional, albeit shorter, dystrophin protein, thereby slowing disease progression and improving clinical outcomes. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) in 2023-2024, up from 2,681 patients in 2022-2023. Therefore, the expanding availability of genetic testing is driving the growth of the amondys 45 market.

The growing demand for personalized medicine is expected to propel the expansion of the amondys 45 market going forward. Personalized medicine is a healthcare approach that customizes treatment strategies based on an individual’s genetic profile, environmental influences, and lifestyle factors to enhance outcomes and improve care quality. Demand for personalized medicine is rising due to advances in genomic technologies that enable the accurate identification of genetic variations and the development of targeted therapies. Amondys 45 strengthens personalized medicine by offering a mutation-specific treatment option for patients with Duchenne muscular dystrophy whose genetic profiles are amenable to exon 45 skipping. This targeted mechanism improves treatment precision and supports better clinical outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from 12 approvals in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the amondys 45 market.

The increase in healthcare expenditure is expected to drive the growth of the amondys 45 market in the coming years. Healthcare expenditure refers to the total financial resources allocated to healthcare services, including medical treatments, infrastructure development, and healthcare programs. The rise in healthcare spending is driven by several interconnected factors, such as an aging population, advancements in medical technology, a growing prevalence of chronic diseases, inflation and rising costs of medical supplies, and increasing expectations for high-quality care. Amondys 45 contributes to healthcare expenditure by offering a specialized, targeted therapy for Duchenne muscular dystrophy, which, while improving patient outcomes, requires substantial investment in advanced treatments and ongoing healthcare support. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure rose by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, rising healthcare expenditure is driving the growth of the amondys 45 market.

Major companies operating in the amondys 45 market are Sarepta Therapeutics Inc.

North America was the largest region in the amondys 45 market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the amondys 45 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the amondys 45 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the amondys 45 market by increasing costs for oligonucleotide synthesis materials, specialized manufacturing equipment, and controlled distribution logistics. These impacts affect hospital pharmacies and specialty treatment centers. North america faces pricing pressure due to advanced therapy import reliance. However, tariffs are encouraging localized production of rare disease therapeutics. This strengthens long-term access and supply reliability.

The amondys 45 market research report is one of a series of new reports that provides amondys 45 market statistics, including amondys 45 industry global market size, regional shares, competitors with a amondys 45 market share, detailed amondys 45 market segments, market trends and opportunities, and any further data you may need to thrive in the amondys 45 industry. This amondys 45 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Amondys 45 (casimersen) is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation that is amenable to exon 45 skipping. It is an antisense oligonucleotide therapy that functions by targeting and skipping exon 45 during gene transcription, thereby enabling the production of a functional, though shortened, dystrophin protein.

The primary indications for amondys 45 include Duchenne muscular dystrophy (DMD) with an exon 45 mutation and other genetic mutations. Duchenne muscular dystrophy (DMD) exon 45 mutation refers to a genetic form of DMD caused by alterations in the DMD gene affecting exon 45, resulting in insufficient dystrophin protein that is essential for muscle cell structure and function. The therapy is used by pediatric, adult, and geriatric patients and is distributed through various channels, including hospitals, retail pharmacies, and online pharmacies.

The amondys 45 market consists of sales of injectable solutions and antisense oligonucleotide products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.